Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma by Narendranath Epperla, Loretta J. Nastoupil, Bruce Feinberg, John Galvin, Prathamesh Pathak, Theresa Amoloja, Danielle Gentile, Kim Saverno

Get full text

Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas by Elise A. Chong, Elicia Penuel, Ellen B. Napier, Rachel K. Lundberg, Lihua E. Budde, Mazyar Shadman, Matthew J. Matasar, Nancy L. Bartlett, Ian W. Flinn, Francesc Bosch, Keith Fay, Andre Goy, Anita Kumar, Loretta J. Nastoupil, Michael C. Wei, Mei Wu, Shen Yin, Joseph A. Fraietta, Emeline R. Chong, Stephen J. Schuster

Get full text

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas by Gohar S. Manzar, Chelsea C. Pinnix, Stephanie O. Dudzinski, Kathryn E. Marqueen, Elaine E. Cha, Lewis F. Nasr, Alison K. Yoder, Michael K. Rooney, Paolo Strati, Sairah Ahmed, Chijioke Nze, Ranjit Nair, Luis E. Fayad, Michael Wang, Loretta J. Nastoupil, Jason R. Westin, Christopher R. Flowers, Sattva S. Neelapu, Jillian R. Gunther, Bouthaina S. Dabaja, Susan Y. Wu, Penny Q. Fang

Get full text